Indy’s top 11 acquisition deals, before Anthem-Cigna
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Indy’s annual Gen Con convention has become a powerhouse in the growing $880 million international hobby game business—and a boon for homegrown gaming startups, including Plowgames.
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Eli Lilly and Co.’s highly anticipated cholesterol drug passed a “futility analysis,” allowing it to complete a critical Phase 3 study in patients, according to Reuters. The drug, called evacetrapib, is designed to boost "good" HDL cholesterol while lowering "bad" LDL cholesterol. An independent panel of scientific advisers recommended that the clinical trial of the […]
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
Innovative thinking can help Indiana maintain its leadership in the life sciences, can boost Indiana’s economy, and can bring even more important medical breakthroughs to market.
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
A jury found Lilly isn't liable for withdrawal symptoms experienced by a woman who quit the antidepressant Cymbalta. The verdict may give the drugmaker leverage in fending off more than 5,000 other lawsuits over the drug.
Wheaton has bought a string of companies, including Bekins Van Lines, which required Jarrod Carter and his team to make a series of imporant decisions about which technology systems to ditch or adapt.
Mike Meadows helped with the massive task of taking Lilly’s IT organization through a downsizing that reduced expenses about 40 percent—with no significant IT service disruptions.
The Fishers Redevelopment Commission approved a resolution Monday that would allow the city to sublease space in the Meyer Najem headquarters on Lantern Road to 12 Stars Media.
Previous Top Honorees are not eligible for nomination. Remaining honorees are eligible. 2019 Not-For-Profit/Government Todd Davis, Hendricks Regional Health Steve Herriford, University of Indianapolis Peter Williams, Butler University – Top Honoree Private Company — Under $100M Joe Gadell, GadellNet Consulting Services Curt Knapp, Perq – Top Honoree Alan Pyrz, eGov Strategies Private Company — Over […]
Lilly currently employs 4,400 R&D workers in Indianapolis—more than half of our 8,000 R&D employees worldwide.
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Marion County has struggled since the end of the Great Recession in attracting the most valuable jobs and workers.
While businesses consider many factors before choosing where to locate, economic development experts say a community’s openness to lesbian, gay, bisexual and transgender individuals increasingly is one of them.
A wave of fear triggered by instability in China initially doused U.S. stocks on Monday morning, but then quickly receded by noon.
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.